Christina A Spivey1, Jenny Griffith2, Cameron Kaplan3, Arnold Postlethwaite3, Arijit Ganguli2, Junling Wang4. 1. University of Tennessee Health Science Center College of Pharmacy, Memphis, TN, USA. 2. Health Economics and Outcomes Research, AbbVie, North Chicago, IL, USA. 3. University of Tennessee Health Science Center College of Medicine, Memphis, TN, USA. 4. University of Tennessee Health Science Center College of Pharmacy, Memphis, TN, USA. jwang26@uthsc.edu.
Abstract
INTRODUCTION: Understanding the effects of corticosteroid utilization prior to initiation of biologic disease-modifying antirheumatic drugs (DMARDs) can inform decision-makers on the appropriate use of these medications. This study examined treatment patterns and associated burden of corticosteroid utilization before initiation of biologic DMARDs among rheumatoid arthritis (RA) patients. METHODS: A retrospective analysis was conducted of adult RA patients in the US MarketScan Database (2011-2015). The following patterns of corticosteroid utilization were analyzed: whether corticosteroids were used; duration of use (short/long duration defined as < or ≥ 3 months); and dosage (low as < 2.5, medium as 2.5 to < 7.5 and high as ≥ 7.5 mg/day). Effects of corticosteroid use on time to biologic DMARD initiation were examined using Cox proportional hazards models. Likelihood and number of adverse events were examined using logistic and negative binomial regression models. Generalized linear models were used to examine healthcare costs. Independent variables in all models included patient demographics and health characteristics. RESULTS: A total of 25,542 patients were included (40.84% used corticosteroids). Lower hazard of biologic DMARD initiation was associated with corticosteroid use (hazard ratio = 0.89, 95% confidence interval = 0.83-0.96), long duration and lower dose. Corticosteroid users compared to non-users had higher incidence rates of various adverse events including cardiovascular events (P < 0.05). Higher likelihood of adverse events was associated with corticosteroid use and long duration of use, as was increased number of adverse events. Corticosteroid users had a greater annualized mean number of physician visits, hospitalizations, and emergency department (ED) visits than non-users in adjusted analysis. Corticosteroid users compared to non-users had higher mean costs for total healthcare, physician visits, hospitalizations, and ED visits. CONCLUSIONS: Among patients with RA, corticosteroid utilization is associated with delayed initiation of biologic DMARDS and higher burden of adverse events and healthcare utilization/costs before the initiation of biologic DMARDs. FUNDING: AbbVie Inc.
INTRODUCTION: Understanding the effects of corticosteroid utilization prior to initiation of biologic disease-modifying antirheumatic drugs (DMARDs) can inform decision-makers on the appropriate use of these medications. This study examined treatment patterns and associated burden of corticosteroid utilization before initiation of biologic DMARDs among rheumatoid arthritis (RA) patients. METHODS: A retrospective analysis was conducted of adult RApatients in the US MarketScan Database (2011-2015). The following patterns of corticosteroid utilization were analyzed: whether corticosteroids were used; duration of use (short/long duration defined as < or ≥ 3 months); and dosage (low as < 2.5, medium as 2.5 to < 7.5 and high as ≥ 7.5 mg/day). Effects of corticosteroid use on time to biologic DMARD initiation were examined using Cox proportional hazards models. Likelihood and number of adverse events were examined using logistic and negative binomial regression models. Generalized linear models were used to examine healthcare costs. Independent variables in all models included patient demographics and health characteristics. RESULTS: A total of 25,542 patients were included (40.84% used corticosteroids). Lower hazard of biologic DMARD initiation was associated with corticosteroid use (hazard ratio = 0.89, 95% confidence interval = 0.83-0.96), long duration and lower dose. Corticosteroid users compared to non-users had higher incidence rates of various adverse events including cardiovascular events (P < 0.05). Higher likelihood of adverse events was associated with corticosteroid use and long duration of use, as was increased number of adverse events. Corticosteroid users had a greater annualized mean number of physician visits, hospitalizations, and emergency department (ED) visits than non-users in adjusted analysis. Corticosteroid users compared to non-users had higher mean costs for total healthcare, physician visits, hospitalizations, and ED visits. CONCLUSIONS: Among patients with RA, corticosteroid utilization is associated with delayed initiation of biologic DMARDS and higher burden of adverse events and healthcare utilization/costs before the initiation of biologic DMARDs. FUNDING: AbbVie Inc.
Authors: Gabriela Schmajuk; Amal N Trivedi; Daniel H Solomon; Edward Yelin; Laura Trupin; Eliza F Chakravarty; Jinoos Yazdany Journal: JAMA Date: 2011-02-02 Impact factor: 56.272
Authors: Jeffrey R Curtis; Andrew O Westfall; Jeroan Allison; Johannes W Bijlsma; Allison Freeman; Varghese George; Stacey H Kovac; Claire M Spettell; Kenneth G Saag Journal: Arthritis Rheum Date: 2006-06-15
Authors: Amalia A van Everdingen; Johannes W G Jacobs; Dirk R Siewertsz Van Reesema; Johannes W J Bijlsma Journal: Ann Intern Med Date: 2002-01-01 Impact factor: 25.391
Authors: K G Saag; R Koehnke; J R Caldwell; R Brasington; L F Burmeister; B Zimmerman; J A Kohler; D E Furst Journal: Am J Med Date: 1994-02 Impact factor: 4.965
Authors: V F Panoulas; K M J Douglas; A Stavropoulos-Kalinoglou; G S Metsios; P Nightingale; M D Kita; M S Elisaf; G D Kitas Journal: Rheumatology (Oxford) Date: 2008-01 Impact factor: 7.580
Authors: Jinoos Yazdany; Chris Tonner; Gabriela Schmajuk; Grace A Lin; Amal N Trivedi Journal: Arthritis Care Res (Hoboken) Date: 2014-10 Impact factor: 4.794
Authors: Boulos Haraoui; Algis Jovaisas; William G Bensen; Rafat Faraawi; John Kelsall; Sanjay Dixit; Jude Rodrigues; Maqbool Sheriff; Emmanouil Rampakakis; John S Sampalis; Allen J Lehman; Susan Otawa; Francois Nantel; May Shawi Journal: RMD Open Date: 2015-04-29
Authors: Michael D George; Brian C Sauer; Chia-Chen Teng; Grant W Cannon; Bryant R England; Gail S Kerr; Ted R Mikuls; Joshua F Baker Journal: J Rheumatol Date: 2018-10-01 Impact factor: 4.666
Authors: Neil M Schultz; David F Penson; Samuel Wilson; Yan Song; Hongbo Yang; Krishnan Ramaswamy; Benjamin Lowentritt Journal: Drug Saf Date: 2020-01 Impact factor: 5.606
Authors: Christina A Spivey; Kevin L Winthrop; Jenny Griffith; Cameron M Kaplan; Yanru Qiao; Arnold E Postlethwaite; Junling Wang Journal: Rheumatol Ther Date: 2019-11-18
Authors: Kathleen M Andersen; Orit Schieir; Marie-France Valois; Susan J Bartlett; Louis Bessette; Gilles Boire; Boulos Haraoui; Glen Hazlewood; Carol Hitchon; Edward C Keystone; Janet Pope; Diane Tin; J Carter Throne; Vivian P Bykerk Journal: ACR Open Rheumatol Date: 2021-10-28